Infinity Pharma

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. It focuses on its drug development segment. The company was founded by Steven H. Holtzman and Matthew D. Shair on March 22, 1995 and is headquartered in Cambridge, MA.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors

SAN DIEGO--(BUSINESS WIRE)---- $INFI #InfinityPharmaceuticals--Infinity Pharmaceuticals, Inc. (INFI) Misled Investors Regarding its Business Prospects.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Applied Infinity Pharmaceuticals, Inc. (INFI)

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Infinity Pharmaceuticals, Inc. (INFI) (“Infinity” or the “Company”) (Nasdaq: INFI) securities between January 5, 2022 and July 24, 2023, inclusive (the “Class Period”). Infinity investors have until October 16, 2023 to file a lead plaintiff motion. If you suffered a loss.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 16, 2023. SO WHAT: If you purchased Infinity securities during.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INFI

Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.

Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals today announced a series of actions designed to reduce burn rate and enhance ability to maximize value of eganelisib.

Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with.

Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

MEI Pharma

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential.

MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company's special meeting on July 23, 2023, at 10:00 a.m. Eastern Time: Dear Fellow MEI Shareholders, We have extended the opportunity for shareholders to vote FOR our pending transaction with Infinity Pharmaceuticals, Inc. If you h.

MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”) at the special meeting of Infinity stockholders held earlier today (the “Special Me.

Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma

Infinity Pharma (INFI) provides insights on the phase II MARIO-8 study design. The study will evaluate eganelisib for squamous cell cancer of the head and neck.

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. MEI issued the following statement: With the special meeting just days away, now is the time for MEI shareholders to vote FOR our pending Infinity transaction. As a reminder, Independent leading proxy advisory firms, IS.

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced further design features of its Phase 2 MARIO-8 study in SCCHN. The adaptive design of the MARIO-8 study is intended to optimize the dose of the oral drug candidate, eganelisib, in combination with the standard dose of pembrolizumab, in 40-70 patients.

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. The Company noted that leading proxy advisory firm Glass Lewis joined ISS in recommending that shareholders vote FOR the transaction. MEI issued the following statement: MEI shareholders have the opportunity to particip.

MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals announced today that ISS has recommended that Infinity stockholders vote for the merger with MEI Pharma, Inc.

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that MEI Pharma shareholders vote “FOR” the Company's pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. MEI issued the following statement in response to the report: We are pleased that ISS supports our.

MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following letter to shareholders reiterating the Board of Directors recommendation to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company's special meeting on July 14, 2023: Dear Fellow MEI Shareholders, The special meeting of shareholders at which you will have the opportunity to vote FOR our pending transaction with Infinity P.

MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Infinity Pharmaceuticals, Inc. (the “Company”) (NasdaqGS: INFI) with MEI Pharma, Inc. (NasdaqCM: MEIP). Under the terms of the proposed transaction, Infinity shareholders will end up owning 42.0% of the outstanding equity of the combined company. KSF is seeking to determine whether the merger and the process.

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced upcoming presentations including data on eganelisib by Infinity's collaborator, Professor Judith A.

Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research

Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its full year 2022 financial results.

Infinity Pharmaceuticals Reports Full Year 2022 Financial Results

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know

AdaptHealth Corp

Cara Therapeutics

OptimizeRx Corp

Alpha Teknova

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

NEW YORK , Feb. 28, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI), in connection with its proposed merger with MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI Pharma").  Under the terms of the merger agreement, Infinity will become a wholly owned subsidiary of MEI Pharma.

News for Infinity Pharma Stock (INFI)